INSY# Stock
L*8
1 楼
INSYS Therapeutics, Inc., a development stage company, develops
pharmaceutical products that target the unmet needs of cancer patients, with
a focus on cancer-supportive care. The company’s cancer-supportive care
and cancer therapy product candidates include Fentanyl sublingual spray, a
single-use product for the treatment of breakthrough cancer pain; and
Dronabinol SG capsule, an ANDA approved product and Dronabinol Oral Solution
, which completed Phase II clinical trials for the treatment of chemotherapy
-induced nausea and vomiting, and appetite stimulation in AIDS patients. It
also develops proprietary cancer therapeutics comprising LEP-ETU, a NeoLipid
liposomal, which is in Phase II clinical development stage to enhance
efficacy and reduce paclitaxel-related side effects. The company was founded
in 2002 and is based in Phoenix, Arizona.
pharmaceutical products that target the unmet needs of cancer patients, with
a focus on cancer-supportive care. The company’s cancer-supportive care
and cancer therapy product candidates include Fentanyl sublingual spray, a
single-use product for the treatment of breakthrough cancer pain; and
Dronabinol SG capsule, an ANDA approved product and Dronabinol Oral Solution
, which completed Phase II clinical trials for the treatment of chemotherapy
-induced nausea and vomiting, and appetite stimulation in AIDS patients. It
also develops proprietary cancer therapeutics comprising LEP-ETU, a NeoLipid
liposomal, which is in Phase II clinical development stage to enhance
efficacy and reduce paclitaxel-related side effects. The company was founded
in 2002 and is based in Phoenix, Arizona.
